Citation: Hickey S, Roberts H (2005) Misleading Information on the Properties of Vitamin C. PLoS Med2(9): e307. https://doi.org/10.1371/journal.pmed.0020307
Published: September 27, 2005
Copyright: © 2005 Hickey and Roberts. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: The authors have declared that no competing interests exist.
The Cochrane review by Douglas et al. , which is referenced in the Best Practice article by Douglas and Hemilä , covers 60 years of research into vitamin C and the common cold. However, the review omits pharmacokinetic data that invalidate the conclusion that vitamin C is ineffective. This conclusion is not derivable from the data presented.
The dual-phase pharmacokinetics of vitamin C are described by the dynamic flow model [3,4]. Low gram-level intakes of ascorbate, leading to blood plasma levels below 70 μM/l, have a half-life of 8–40 days. Higher gram-level intakes have a plasma half-life of 30 minutes . A large oral dose raises blood plasma levels briefly: they reach a peak after two to three hours, before decaying back to baseline. Frequent repeated doses allow sustained high plasma levels of about 250 μM/l [4,5].
Douglas and Hemilä reviewed intakes that transiently raise plasma ascorbate levels above 70 μM/l. A single dose does not raise the median level [6,7]. Daily supplements would, thus, not increase disease resistance to any great degree [3,4]. Single or double doses daily will not increase background plasma levels, regardless of the magnitude of the dose [6,7]. Since plasma ascorbate is at background level for the majority of the day, effects will be minimal.
There is widespread confusion about nutritional and pharmacological levels of supplementation . Linus Pauling, typically, described nutritional gram-level doses able to provide a degree of disease prevention . By contrast, pharmacological doses used for treatment are, at minimum, an order of magnitude larger and involve frequent doses. The doses should be at intervals of three hours or less . Treatment doses are described by Cathcart's paper on titration to bowel tolerance . To treat the onset of a cold, the therapy is perhaps a minimum of 10 g of oral ascorbic acid, followed by at least 2 g each hour [3,4].
Douglas and Hemilä give a misleading impression by not making it clear that the doses they consider are not pharmacological. They claim that the results of one study, giving an 8-g dose at the start of symptoms, are tantalising and deserve further assessment. However, once this single dose has been excreted, the protective effects will be lost. During illness, ascorbate is depleted rapidly and higher oral intakes are tolerated—up to 200 g per day . It would be surprising if this 8-g dose had a large effect.
Studies on ascorbate require appropriate doses. Douglas and Hemilä have only confirmed that 60 years of vitamin C research has largely been wasted because of confusion between nutritional and pharmacological intakes, and because of a misunderstanding of the pharmacokinetics. It is essential that high-dose studies take into account ascorbate's dual-phase pharmacokinetics. The dosing regime should allow sustained high plasma levels to be achieved. The claim that vitamin C cannot prevent or cure the common cold is both premature and unwarranted.
- 1. Douglas RM, Hemilä H, D'Souza R, Chalker EB, Treacy B (2004) Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 4: CD000980.RM DouglasH. HemiläR. D'SouzaEB ChalkerB. TreacyVitamin C for preventing and treating the common cold.Cochrane Database Syst Rev20044CD000980pub2. pub2.
- 2. Douglas RM, Hemilä H (2005) Vitamin C for preventing and treating the common cold. PLoS Med 2: e168.RM DouglasH. HemiläVitamin C for preventing and treating the common cold.PLoS Med20052e168
- 3. Hickey S, Roberts HJ (2004) Ascorbate: The science of vitamin C. Napa (California): Lulu Press. 264 p.S. HickeyHJ RobertsAscorbate: The science of vitamin C2004Napa (California)Lulu Press
- 4. Hickey S, Roberts HJ, Cathcart RF (2005) Dynamic flow: A new model for ascorbate. J Orthomol Med. S. HickeyHJ RobertsRF CathcartDynamic flow: A new model for ascorbate.J Orthomol Med2005In press. In press.
- 5. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, et al. (2004) Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 140: 533–537.SJ PadayattyH. SunY. WangHD RiordanSM HewittVitamin C pharmacokinetics: Implications for oral and intravenous use.Ann Intern Med2004140533537
- 6. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, et al. (1996) Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 93: 3704–3709.M. LevineC. Conry-CantilenaY. WangRW WelchPW WashkoVitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance.Proc Natl Acad Sci U S A19969337043709
- 7. Levine M, Wang Y, Padayatty SJ, Morrow J (2001) A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 98: 9842–9846.M. LevineY. WangSJ PadayattyJ. MorrowA new recommended dietary allowance of vitamin C for healthy young women.Proc Natl Acad Sci U S A20019898429846
- 8. Pauling L (1970) Vitamin C and the common cold. New York: W. H. Freeman. 122 p.L. PaulingVitamin C and the common cold1970New YorkW. H. Freeman
- 9. Cathcart RF (1981) Vitamin C, titrating to bowel tolerance, anascoremia, and acute induced scurvy. Med Hypotheses 7: 1359–1376.RF CathcartVitamin C, titrating to bowel tolerance, anascoremia, and acute induced scurvy.Med Hypotheses1981713591376